Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Chikungunya Fever Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Chikungunya Fever Overview | 11 | 1 |
| Pipeline Products for Chikungunya Fever Comparative Analysis | 12 | 1 |
| Chikungunya Fever Therapeutics under Development by Companies | 13 | 2 |
| Chikungunya Fever Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Chikungunya Fever Pipeline Products Glance | 16 | 2 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Chikungunya Fever Products under Development by Companies | 18 | 1 |
| Chikungunya Fever Products under Investigation by Universities/Institutes | 19 | 1 |
| Chikungunya Fever Companies Involved in Therapeutics Development | 20 | 19 |
| Abivax S.A. | 20 | 1 |
| Arbovax, Inc. | 21 | 1 |
| Arno Therapeutics, Inc. | 22 | 1 |
| Bharat Biotech International Limited | 23 | 1 |
| Ennaid Therapeutics, LLC | 24 | 1 |
| Etubics Corporation | 25 | 1 |
| Hawaii Biotech, Inc. | 26 | 1 |
| HSRx Group | 27 | 1 |
| Indian Immunologicals Limited | 28 | 1 |
| Inovio Pharmaceuticals, Inc. | 29 | 1 |
| Integral Molecular, Inc. | 30 | 1 |
| Integrated BioTherapeutics, Inc. | 31 | 1 |
| Merck &Co., Inc. | 32 | 1 |
| Nanotherapeutics, Inc. | 33 | 1 |
| Profectus BioSciences, Inc. | 34 | 1 |
| Takeda Pharmaceutical Company Limited | 35 | 1 |
| Themis Bioscience GmbH | 36 | 1 |
| Valneva SE | 37 | 1 |
| Vaxart, Inc. | 38 | 1 |
| Chikungunya Fever Therapeutics Assessment | 39 | 9 |
| Assessment by Monotherapy Products | 39 | 1 |
| Assessment by Target | 40 | 2 |
| Assessment by Mechanism of Action | 42 | 2 |
| Assessment by Route of Administration | 44 | 2 |
| Assessment by Molecule Type | 46 | 2 |
| Drug Profiles | 48 | 41 |
| ABX-1089 Drug Profile | 48 | 1 |
| ABX-1091 Drug Profile | 49 | 1 |
| ABX-311 Drug Profile | 50 | 1 |
| Antibody for Chikungunya Drug Profile | 51 | 1 |
| AR-12 Drug Profile | 52 | 3 |
| chikungunya (viral like particles) vaccine Drug Profile | 55 | 1 |
| chikungunya vaccine Drug Profile | 56 | 1 |
| chikungunya vaccine Drug Profile | 57 | 2 |
| chikungunya vaccine Drug Profile | 59 | 1 |
| chikungunya vaccine Drug Profile | 60 | 1 |
| chikungunya vaccine Drug Profile | 61 | 1 |
| chikungunya vaccine Drug Profile | 62 | 1 |
| chikungunya vaccine Drug Profile | 63 | 1 |
| chikungunya vaccine Drug Profile | 64 | 1 |
| chikungunya vaccine Drug Profile | 65 | 1 |
| chikungunya vaccine Drug Profile | 66 | 1 |
| chikungunya vaccine Drug Profile | 67 | 1 |
| chikungunya vaccine Drug Profile | 68 | 1 |
| chikungunya vaccine Drug Profile | 69 | 1 |
| chikungunya vaccine Drug Profile | 70 | 1 |
| chikungunya vaccine Drug Profile | 71 | 1 |
| chikungunya vaccine Drug Profile | 72 | 1 |
| DEF-201 Drug Profile | 73 | 2 |
| HSRx-431 Drug Profile | 75 | 1 |
| IMCKV-063 Drug Profile | 76 | 1 |
| Monoclonal Antibodies for Chikungunya Drug Profile | 77 | 1 |
| Monoclonal Antibodies for Equine Encephalitis and Chikungunya Drug Profile | 78 | 1 |
| Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya Drug Profile | 79 | 1 |
| Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever Drug Profile | 80 | 1 |
| Monoclonal Antibody for Chikungunya Drug Profile | 81 | 1 |
| MV-CHIK Drug Profile | 82 | 2 |
| Peptides for Infectious Diseases Drug Profile | 84 | 1 |
| Small Molecule to Inhibit NS2 and NS3 for Chikungunya Drug Profile | 85 | 1 |
| Small Molecules for Chikungunya Drug Profile | 86 | 1 |
| Synthetic Peptides for Chikungunya Drug Profile | 87 | 1 |
| Tatbeclin-1 Drug Profile | 88 | 1 |
| Chikungunya Fever Dormant Projects | 89 | 1 |
| Chikungunya Fever Product Development Milestones | 90 | 10 |
| Featured News &Press Releases | 90 | 1 |
| Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine | 90 | 1 |
| Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2 | 91 | 1 |
| Mar 22, 2016: Inovio s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study | 91 | 2 |
| Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs | 93 | 1 |
| Mar 02, 2015: Themis Bioscience s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases | 94 | 1 |
| Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus | 95 | 1 |
| Nov 20, 2014: Themis Bioscience s Vaccine Against Chikunguya Successful In Phase 1 | 96 | 1 |
| Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful | 97 | 1 |
| Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate | 97 | 1 |
| Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine | 98 | 1 |
| Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models | 98 | 1 |
| Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development | 99 | 1 |
| Appendix | 100 | 2 |
| Methodology | 100 | 1 |
| Coverage | 100 | 1 |
| Secondary Research | 100 | 1 |
| Primary Research | 100 | 1 |
| Expert Panel Validation | 100 | 1 |
| Contact Us | 100 | 1 |
| Disclaimer | 101 | 1 |